Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents
Bispecific agents are a rapidly growing class of cancer therapeutics, and immune targeted bispecific agents have the potential to expand functionality well beyond monoclonal antibody agents. Humabodies⁎⁎ Humabody® is a registered trademark of Crescendo Biologics Ltd. are fully human single domain an...
Main Authors: | Anna Kopp, Hyeyoung Kwon, Colette Johnston, Steven Vance, James Legg, Laurie Galson-Holt, Greg M. Thurber |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558623000854 |
Similar Items
-
Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01) -
Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
by: Filippo Benedetti, et al.
Published: (2021-07-01) -
Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01) -
Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
by: Jie Chen, et al.
Published: (2023-07-01) -
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01)